IP Library Granted Patent US 8,816,093
Granted Patent B2
US 8,816,093 · App. 13/913,876 · Granted Aug 26, 2014

Processes for producing cycloalkylcarboxamido-pyridine benzoic acids

Inventor: David Andrew Siesel (San Diego, CA)
Assignee: Vertex Pharmaceuticals Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,816,093
App. No.
13/913,876
Granted
Aug 26, 2014
Kind
B2
Abstract

The present invention relates to a process of providing the 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid in substantially free form (Compound 1).

Claims (61)

1. A process for preparing a compound of formula 1:

comprising the step of:

ia) reacting a compound of formula 6a:

wherein,

R is H, C 1-6 aliphatic, aryl, aralkyl, heteroaryl, cycloalkyl, or heterocycloalkyl;

R 1 is independently selected from —R J , —OR J , —N(R J ) 2 , —NO 2 , halogen, —CN, —C 1-4 haloalkyl, —C 1-4 haloalkoxy, —C(O)N(R J ) 2 , —NR J C(O)R J , —SOR J , —SO 2 R J , —SO 2 N(R J ) 2 , —NR J SO 2 R J , —COR J , —CO 2 R J , —NR J SO 2 N(R J ) 2 , —COCOR J ;

R J is hydrogen or C 1-6 aliphatic;

o is an integer from 0 to 3 inclusive; and

p is an integer from 0 to 5 inclusive;

with a compound of formula 7a:

wherein,

A is a fused cycloalkyl, or heterocycloalkyl ring;

R 1 is independently selected from —R J , —OR J , —N(R J ) 2 , —NO 2 , halogen, —CN, —C 1-4 -haloalkyl, —C 1-4 -haloalkoxy, —C(O)N(R J ) 2 , —NR J C(O)R J , —SOR J , —SO 2 R J , —SO 2 N(R J ) 2 , —NR J SO 2 R J , —COR J , —CO 2 R J , —NR J SO 2 N(R J ) 2 , —COCOR J ;

R J is hydrogen or C 1-6 aliphatic;

m is an integer from 0 to 3 inclusive;

n is an integer from 1 to 4 inclusive; and

X is a halo or OH;

in an organic solvent in the presence of a second base,

wherein compound 7a is prepared by the following steps

ic) reducing Compound 10a in an organic solvent:

wherein,

A is a fused cycloalkyl or heterocycloalkyl ring;

R 1 is independently selected from —R J , —OR J , —N(R J ) 2 , —NO 2 , halogen, —CN, —C 1-4 -haloalkyl, —C 1-4 -haloalkoxy, —C(O)N(R J ) 2 , —NR J C(O)R J , —SOR J , —SO 2 R J , —SO 2 N(R J ) 2 , —NR J SO 2 R J , —COR J , —CO 2 R J , —NR J SO 2 N(R J ) 2 , —COCOR J ;

R J is hydrogen or C 1-6 aliphatic;

R K is methyl; and

m is an integer from 0 to 3 inclusive,

with a reducing agent to produce Compound 11a:

wherein, ring A, R 1 , and m are as defined in Compound 10a above;

iic) reacting Compound 11a with a halogenating agent in an organic solvent to produce Compound 12a:

wherein, ring A, R 1 , and m are as defined in Compound 10a above, and Hal is a halide;

iiic) reacting Compound 12a with a cyanide to produce Compound 13a:

wherein, ring A, R 1 , and m are as defined in Compound 10a above;

ivc) reacting Compound 13a with a compound of formula 13aa in the presence of a base:

wherein,

Hal is a halide; and

q is an integer from 0 to 3 inclusive; to produce a compound of formula 14a:

wherein,

r is an integer from 1 to 4 inclusive; and

ring A, R 1 , and m are as defined in Compound 10a above;

vc) sequentially reacting Compound 14a with a hydroxide base and acid to form Compound 15a, which is compound 7a when X═OH:

wherein, r, ring A, R 1 , and m are as defined in Compound 14a above; and

vic) reacting Compound 15a with a halogenating agent in an organic solvent to form Compound 16a, which is compound 7a when X=halide:

wherein,

Hal is halide; and

r, ring A, R 1 , and m are as defined in Compound 14a above.

2. The process of claim 1 , wherein the reaction between compound 6a and compound 7a is carried out in the presence of a catalytic amine.

3. The process of claim 1 , wherein the reaction between compound 6a and compound 7a is carried out in the presence of a catalytic amount of dimethylaminopyridine.

4. The process of claim 1 , wherein when R 1 on the phenyl ring in formula 1 is an ester, the process further comprises de-esterifying the compound of formula 1 in a biphasic mixture comprising water, an organic solvent, and an acid to give an acid salt.

5. The process of claim 4 , wherein the organic solvent is acetonitrile.

6. The process of claim 4 , the acid is an inorganic acid.

7. The process of claim 4 , wherein the acid is hydrochloric acid.

8. The process of claim 4 , wherein the de-esterification reaction is run at between 20° C. and 60° C.

9. The process of claim 4 , wherein the acid salt is converted to the free form, Form I, by slurrying or dissolving the acid salt in a solvent for an effective amount of time.

10. The process of claim 9 , wherein the solvent is selected from water or a 50% methanol/water mixture.

11. The process of claim 9 , wherein the solvent is water.

12. The process of claim 9 , wherein the effective amount of time is between 2 and 24 hours.

13. The process of claim 9 , further comprising the step of filtering the slurry of the compound of formula I in Form I, or concentrating the solution of the compound of formula I in Form I to effect recrystallization and filtering the recrystallized compound of formula I in Form I.

14. The process of claim 1 , wherein the compound of formula 7a is

15. The process of claim 1 , wherein the compound of formula 6a is

16. The process of claim 4 , wherein the compound of formula I is

17. The process of claim 9 , wherein the compound of formula I is

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2017
From: MILLER, MARK THOMAS; MCCARTNEY, JASON; HADIDA RUAH, SARA SABINA; ZHOU, JINGLAN
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 043203/0136 →
RELEASE OF SECURITY INTEREST Recorded Oct 14, 2016
From: MACQUARIE US TRADING LLC
To: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
Reel/Frame 040357/0001 →
ASSIGNEE CHANGE OF ADDRESS Recorded Feb 11, 2016
From: VERTEX PHARMACEUTICALS INCORPORATED
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 037781/0332 →
SECURITY INTEREST Recorded Jul 10, 2014
From: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 033292/0311 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2013
From: SIESEL, DAVID
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 031628/0826 →
Continuity (6)
Continuation 13450805 · Apr 19, 2012
Continuation 12474590 · May 29, 2009
Continuation In Part 12327915 · Dec 4, 2008
Provisional Application 61012181 · Dec 7, 2007
Provisional Application 61109573 · Oct 30, 2008
Related Publication 20130274477A1 · Oct 17, 2013